-+ 0.00%
-+ 0.00%
-+ 0.00%

According to Zhitong Finance App, Yipinhong (300723.SZ) announced that a phase II/III clinical trial of AR882 (generic name: deuteropentinolate) capsules for treating patients with gout with hyperuricemia, led by Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the company, recently obtained top-line analysis data. Preliminary statistical results showed that AR882 showed positive efficacy and good safety in participants with gout with hyperuricemia. The test results were ideal and achieved the intended goals.

Zhitongcaijing·09/03/2026 09:57:07
Listen to the news
According to Zhitong Finance App, Yipinhong (300723.SZ) announced that a phase II/III clinical trial of AR882 (generic name: deuteropentinolate) capsules for treating patients with gout with hyperuricemia, led by Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the company, recently obtained top-line analysis data. Preliminary statistical results showed that AR882 showed positive efficacy and good safety in participants with gout with hyperuricemia. The test results were ideal and achieved the intended goals.